These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26926119)

  • 1. Targeting α-synuclein: Therapeutic options.
    Dehay B; Decressac M; Bourdenx M; Guadagnino I; Fernagut PO; Tamburrino A; Bassil F; Meissner WG; Bezard E
    Mov Disord; 2016 Jun; 31(6):882-8. PubMed ID: 26926119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.
    Vekrellis K; Stefanis L
    Expert Opin Ther Targets; 2012 Apr; 16(4):421-32. PubMed ID: 22480256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
    Yasuda T; Mochizuki H
    Apoptosis; 2010 Nov; 15(11):1312-21. PubMed ID: 20221696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
    Xilouri M; Brekk OR; Stefanis L
    Mov Disord; 2016 Feb; 31(2):178-92. PubMed ID: 26813776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The vicious cycle between α-synuclein aggregation and autophagic-lysosomal dysfunction.
    Bellomo G; Paciotti S; Gatticchi L; Parnetti L
    Mov Disord; 2020 Jan; 35(1):34-44. PubMed ID: 31729779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
    Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
    Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological role of lipid interaction with α-synuclein in Parkinson's disease.
    Suzuki M; Sango K; Wada K; Nagai Y
    Neurochem Int; 2018 Oct; 119():97-106. PubMed ID: 29305919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.
    Tolmasov M; Djaldetti R; Lev N; Gilgun-Sherki Y
    Expert Rev Neurother; 2016 May; 16(5):505-13. PubMed ID: 26959397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease.
    Carboni E; Lingor P
    Metallomics; 2015 Mar; 7(3):395-404. PubMed ID: 25648629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy.
    Valera E; Monzio Compagnoni G; Masliah E
    Neuropathol Appl Neurobiol; 2016 Feb; 42(1):95-106. PubMed ID: 26924723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Synuclein ubiquitination and novel therapeutic targets for Parkinson's disease.
    Rott R; Szargel R; Shani V; Bisharat S; Engelender S
    CNS Neurol Disord Drug Targets; 2014; 13(4):630-7. PubMed ID: 24168368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular ATP induces intracellular alpha-synuclein accumulation via P2X1 receptor-mediated lysosomal dysfunction.
    Gan M; Moussaud S; Jiang P; McLean PJ
    Neurobiol Aging; 2015 Feb; 36(2):1209-20. PubMed ID: 25480524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of targeted therapies for Parkinson's disease and related synucleinopathies.
    Sybertz E; Krainc D
    J Lipid Res; 2014 Oct; 55(10):1996-2003. PubMed ID: 24668939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment.
    Poehler AM; Xiang W; Spitzer P; May VE; Meixner H; Rockenstein E; Chutna O; Outeiro TF; Winkler J; Masliah E; Klucken J
    Autophagy; 2014; 10(12):2171-92. PubMed ID: 25484190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From Yeast to Humans: Leveraging New Approaches in Yeast to Accelerate Discovery of Therapeutic Targets for Synucleinopathies.
    Piotrowski JS; Tardiff DF
    Methods Mol Biol; 2019; 2049():419-444. PubMed ID: 31602625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research Priorities on the Role of α-Synuclein in Parkinson's Disease Pathogenesis.
    Burré J; Edwards RH; Halliday G; Lang AE; Lashuel HA; Melki R; Murayama S; Outeiro TF; Papa SM; Stefanis L; Woerman AL; Surmeier DJ; Kalia LV; Takahashi R;
    Mov Disord; 2024 Oct; 39(10):1663-1678. PubMed ID: 38946200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlling the mass action of alpha-synuclein in Parkinson's disease.
    Kim C; Lee SJ
    J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug targets from genetics: α-synuclein.
    Danzer KM; McLean PJ
    CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):712-23. PubMed ID: 21838671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.